% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Viktorsson:275365,
      author       = {K. Viktorsson and T. Rieckmann and M. Fleischmann and M.
                      Diefenhardt and S. Hehlgans and F. Rödel$^*$},
      title        = {{A}dvances in molecular targeted therapies to increase
                      efficacy of (chemo)radiation therapy.},
      journal      = {Strahlentherapie und Onkologie},
      volume       = {199},
      number       = {12},
      issn         = {0179-7158},
      address      = {Heidelberg},
      publisher    = {Springer Medizin},
      reportid     = {DKFZ-2023-00734},
      pages        = {1091-1109},
      year         = {2023},
      note         = {2023 Dec;199(12):1091-1109},
      abstract     = {Recent advances in understanding the tumor's biology in
                      line with a constantly growing number of innovative
                      technologies have prompted characterization of patients'
                      individual malignancies and may display a prerequisite to
                      treat cancer at its patient individual tumor vulnerability.
                      In recent decades, radiation- induced signaling and tumor
                      promoting local events for radiation sensitization were
                      explored in detail, resulting the development of novel
                      molecular targets. A multitude of pharmacological, genetic,
                      and immunological principles, including small molecule- and
                      antibody-based targeted strategies, have been developed that
                      are suitable for combined concepts with radiation (RT) or
                      chemoradiation therapy (CRT). Despite a plethora of
                      promising experimental and preclinical findings, however, so
                      far, only a very limited number of clinical trials have
                      demonstrated a better outcome and/or patient benefit when RT
                      or CRT are combined with targeted agents. The current review
                      aims to summarize recent progress in molecular therapies
                      targeting oncogenic drivers, DNA damage and cell cycle
                      response, apoptosis signaling pathways, cell adhesion
                      molecules, hypoxia, and the tumor microenvironment to impact
                      therapy refractoriness and to boost radiation response. In
                      addition, we will discuss recent advances in nanotechnology,
                      e.g., RNA technologies and protein-degrading
                      proteolysis-targeting chimeras (PROTACs) that may open new
                      and innovative ways to benefit from molecular-targeted
                      therapy approaches with improved efficacy.},
      subtyp        = {Review Article},
      keywords     = {DNA damage response (Other) / Nanoparticles (Other) /
                      Noncoding RNAs (Other) / Radiation sensitization (Other) /
                      Translational research (Other)},
      cin          = {FM01},
      ddc          = {610},
      cid          = {I:(DE-He78)FM01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37041372},
      doi          = {10.1007/s00066-023-02064-y},
      url          = {https://inrepo02.dkfz.de/record/275365},
}